Xu Jie, Li Ji, Zheng Tai-Hao, Bai Lian, Liu Zuo-Jin
Department of Gastrointestinal Surgery, Yongchuan Hospital, Chongqing Medical University, Chongqing, China.
Department of Hepatobiliary Surgery, Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Adv Clin Exp Med. 2016 Sep-Oct;25(5):971-975. doi: 10.17219/acem/36460.
Hepatocellular carcinoma is one of the deadliest types of cancer. Despite improvements in treatment over the past few decades, patient survival remains poor and there is an urgent need for development of targeted therapies. MicroRNAs represent a class of small RNAs, frequently deregulated in human malignancies. We are reviewing the role of microRNA in the development of primary hepatocellular carcinoma and its use as a biomarker for early diagnosis and clinical treatment. First, we describe the current incidence and possible causes of the incidence of hepatocellular carcinoma, followed by the introduction of microRNA synthesis, maturation and function, and finally we explain the role of microRNA in the development of hepatocellular carcinoma and its clinical value as a biological marker in the diagnosis and treatment of liver cancer. A comprehensive analysis of cellular microRNA is a benefit for early diagnosis of hepatocellular carcinoma and early clinical intervention, and microRNA is considered by some to be a key target of gene therapy to control the occurrence and development of hepatocellular carcinoma..
肝细胞癌是最致命的癌症类型之一。尽管在过去几十年中治疗有所改善,但患者生存率仍然很低,迫切需要开发靶向治疗方法。微小RNA是一类小RNA,在人类恶性肿瘤中经常失调。我们正在综述微小RNA在原发性肝细胞癌发生发展中的作用及其作为早期诊断和临床治疗生物标志物的用途。首先,我们描述肝细胞癌的当前发病率及发病率的可能原因,接着介绍微小RNA的合成、成熟和功能,最后我们解释微小RNA在肝细胞癌发生发展中的作用及其作为肝癌诊断和治疗中生物标志物的临床价值。对细胞微小RNA进行全面分析有利于肝细胞癌的早期诊断和早期临床干预,并且微小RNA被一些人认为是控制肝细胞癌发生发展的基因治疗的关键靶点。